JP2018538367A - ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 - Google Patents

ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 Download PDF

Info

Publication number
JP2018538367A
JP2018538367A JP2018545568A JP2018545568A JP2018538367A JP 2018538367 A JP2018538367 A JP 2018538367A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018538367 A JP2018538367 A JP 2018538367A
Authority
JP
Japan
Prior art keywords
alx
fpr2
treatment
receptor
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018545568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538367A5 (https=
Inventor
ジャセク・オストロウスキー
リカルド・ガルシア
ニコラス・アール・ワーツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018538367A publication Critical patent/JP2018538367A/ja
Publication of JP2018538367A5 publication Critical patent/JP2018538367A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018545568A 2015-11-24 2016-11-21 ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 Withdrawn JP2018538367A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259498P 2015-11-24 2015-11-24
US62/259,498 2015-11-24
PCT/US2016/063036 WO2017091496A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Publications (2)

Publication Number Publication Date
JP2018538367A true JP2018538367A (ja) 2018-12-27
JP2018538367A5 JP2018538367A5 (https=) 2019-12-19

Family

ID=57544530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018545568A Withdrawn JP2018538367A (ja) 2015-11-24 2016-11-21 ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定

Country Status (13)

Country Link
US (1) US20180325869A1 (https=)
EP (1) EP3380091A1 (https=)
JP (1) JP2018538367A (https=)
KR (1) KR20180081528A (https=)
CN (1) CN108348479A (https=)
AU (1) AU2016359463A1 (https=)
BR (1) BR112018010155A8 (https=)
CA (1) CA3006291A1 (https=)
EA (1) EA201891007A1 (https=)
IL (1) IL259468A (https=)
MX (1) MX2018005756A (https=)
SG (1) SG11201803816RA (https=)
WO (1) WO2017091496A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6811241B2 (ja) 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
WO2018227065A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
EP3634958B1 (en) * 2017-06-09 2021-07-21 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
KR102803660B1 (ko) 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제
CN113166134B (zh) 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
CA3185263A1 (en) 2020-07-09 2022-01-13 James A. Johnson Pyrazolone formyl peptide 2 receptor agonists
KR20230051525A (ko) 2020-08-12 2023-04-18 브리스톨-마이어스 스큅 컴퍼니 옥소피롤리딘 우레아 fpr2 효능제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903378B (zh) * 2007-12-18 2014-03-12 埃科特莱茵药品有限公司 氨基三唑衍生物
CN103221392B (zh) * 2010-11-17 2015-06-03 埃科特莱茵药品有限公司 桥联螺[2.4]庚酯衍生物
CA2871334A1 (en) * 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
JP6811241B2 (ja) * 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
KR102803660B1 (ko) * 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제

Also Published As

Publication number Publication date
US20180325869A1 (en) 2018-11-15
WO2017091496A1 (en) 2017-06-01
BR112018010155A8 (pt) 2019-02-26
CA3006291A1 (en) 2017-06-01
BR112018010155A2 (pt) 2018-11-21
EA201891007A1 (ru) 2018-11-30
KR20180081528A (ko) 2018-07-16
MX2018005756A (es) 2018-08-01
SG11201803816RA (en) 2018-06-28
AU2016359463A1 (en) 2018-07-12
CN108348479A (zh) 2018-07-31
EP3380091A1 (en) 2018-10-03
IL259468A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
JP2018538367A (ja) ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定
Liu et al. Autophagy activation attenuates angiotensin II-induced cardiac fibrosis
Liu et al. Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
CN113318110B (zh) 一种csf-1r激酶抑制剂的用途
CN107072972B (zh) 用伊非曲班治疗心脏纤维化的组合物和方法
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
JP2021075563A (ja) １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP7844766B2 (ja) 抗特発性肺線維症薬ニンテダニブの結核を治療するための使用
KR102354243B1 (ko) 트롬복산-a2 수용체 길항제를 이용한 근위축증 치료 조성물 및 방법
KR20140022052A (ko) 심근 경색 후 환자에서의 심부전 및 부정맥 치료를 위한 ａ２ｂ 아데노신 수용체 안타고니스트의 용도
WO2017189885A1 (en) Ifetroban treatment for systemic sclerosis
US12226455B2 (en) Medical composition for treating cardiac wasting and cachexia
CN108472333B (zh) 组合
US20230114408A1 (en) Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists
CN104220083A (zh) 用于治疗动脉硬化性血管疾病的方法和组合物
EP4117660B1 (en) Methods of modulating t-cell activation and treating chronic heart failure using carboranes
US20260097012A1 (en) Compositions and methods for treating graft-related arrhythmia
JP7233087B2 (ja) 抗動脈硬化剤
WO2026064493A1 (en) Inhibition of farnesyltransferase to treat cardiomyopathy and heart failure
HK40080138A (en) Methods of modulating t-cell activation using carboranes and carborane analogs
WO2026057747A1 (en) Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
WO2025056188A1 (en) Relaxin medication
CN116236477A (zh) 溶血磷脂酸受体5拮抗剂在制备心脏保护药物中的应用
Van De Sandt et al. Pharmacological CCR1 blockade limits infarct size, preserves cardiac function and attenuates left ventricular remodeling in a murine model of myocardial ischemia/reperfusion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191106

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200513